Human Genome Sciences at outperform by JMP

Human Genome Sciences, Inc. was rated at market outperform with a $21.00 price target by JMP Securities analysts Charles C. Duncan and Anthony Ostrea as GlaxoSmithKline decided to co-develop and co-market the company's HGS-ETR1 antibody for cancer. Human Genome stock closed up $0.76, or 6.08%, on Thursday at $13.26 on volume of 3,626,451 shares compared with a three-month trailing average of 2,175,030 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.